FDA

FDA Articles

Trump told Time that he wants to lower drug prices, a move that has hit the drug and biotech segments due to his comments.
Repros Therapeutics saw its shares take a loss on Wednesday after the company provided a key FDA update.
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
Shares of PhaseRx more than doubled on Monday after the company announced that it received a key FDA approval for its rare liver disorder treatment.
Amedica Corp. (NASDAQ: AMDA) is watching its shares drop on Tuesday despite receiving mixed news from the U.S. Food and Drug Administration, along with a new appointment to its management team....
Oragenics Inc. (NYSEMKT: OGEN) saw its shares practically double late on Monday, and even continue climbing after the trading session ended, following an update from the U.S. Food and Drug...
Now that the U.S. presidential election is over and markets have recovered to their highs, there are still some stocks holding back the markets from breaking even higher.
Shares of Aurinia Pharmaceuticals saw a handy gain on Wednesday after the company gave an update on its lupus nephritis treatment.
The U.S. presidential election is now over and markets have seemingly recovered to just below their highs but there are still some laggards.
Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.
Arrowhead Pharmaceuticals shares plummeted early on Wednesday after the company gave an update on its hepatitis B virus treatment.
Shares of Ionis Pharmaceuticals and Biogen were on the move Monday morning after the companies announced positive interim results from a late-stage trial.
Aurinia Pharmaceuticals shares saw a handy gain on Thursday morning after the company announced plans for a late-stage trial in the treatment of lupus nephritis.
Shares of Ariad Pharmaceuticals saw a modest gain early Monday after the company announced a recent FDA decision.
Ariad Pharmaceuticals shares were down handily on Monday after JPMorgan downgraded the stock. Also Senator Sanders recently asked about the pricing of its blood cancer drug Iclusig.